PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Luo, Qing ^a   Huang, Zikun ^a   Ye, Jianqing ^a   Deng, Yating ^a   Fang, Le ^b   Li, Xue ^a   Guo, Yang ^a   Jiang, Hong ^a   Ju, Beihua ^a   Huang, Qingshui ^a   Li, Junming ^a  

^a NANCHANG UNIVERSITY   (China)

^b Xi'an 521 Hospital   (China)

Author keywords

Neutrophils; PD L1; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; B7 ANTIGEN; C REACTIVE PROTEIN; CD40 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; KIDNEY INJURY MOLECULE 1; LA ANTIBODY; NUCLEOSOME ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; RO ANTIBODY; SM ANTIBODY; BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN;

ADULT; ALOPECIA; ANEMIA; ANTIBODY DETECTION; ANTIBODY TITER; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EFFUSION; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROPENIA; FEMALE; FEVER; FLOW CYTOMETRY; HEMATURIA; HUMAN; INFLAMMATION; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEGATIVE FEEDBACK; NEUTROPHIL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; PYURIA; RAYNAUD PHENOMENON; SKIN MANIFESTATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; URINALYSIS; BIOSYNTHESIS; BLOOD; DISEASE COURSE; GENE EXPRESSION REGULATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANTIGENS, CD274; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEUTROPHILS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84957614717     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-0942-0     Document Type: Article

References (37)

1. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:317-25.
2. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363:187-97.
3. Denny MF, Chandaroy P, Killen PD, Caricchio R, Lewis EE, Richardson BC, et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol. 2006;176:2095-104.
4. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184:3284-97.
5. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711-23.
6. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006;25:383-92.
7. Cochrane CG, Unanue ER, Dixon FJ. A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med. 1965;122:99-116.
8. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107:9813-8.
9. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7:691-9.
10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
11. Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 2014;10(3):e1003993. doi: 10.1371/journal.ppat.1003993.
12. Wang JF, Li JB, Zhao YJ, Yi WJ, Bian JJ, Wan XJ, et al. Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study. Anesthesiology. 2015;122:852-63.
13. Buddhisa S, Rinchai D, Ato M, Bancroft GJ, Lertmemongkolchai G. Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions. J Immunol. 2015;194:4413-21.
14. McNab FW, Berry MP, Graham CM, Bloch SA, Oni T, Wilkinson KA, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol. 2011;41:1941-7.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
17. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601-11.
18. Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1985;28:904-13.
19. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken). 2011;63:891-8.
20. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16:283-8.
21. Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, et al. Systemic Lupus International Collaborating Clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58:1784-8.
22. Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, et al. Increased interleukin-9 and CD4 + IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep. 2013;7:1031-7.
23. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20:1267-74.
24. Hock BD, Taylor KG, Cross NB, Kettle AJ, Hampton MB, McKenzie JL. Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology. 2012;137:249-58.
25. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest. 2012;122:327-36.
26. Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60:207-18.
27. Liu MF, Weng CT, Weng MY. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus. J Biomed Biotechnol. 2009;2009:406136.
28. +monocyte in the peripheral blood of patients with systemic lupus erythematosus. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28:429-32.
29. Song LJ, Wang X, Wang XP, Li D, Ding F, Liu HX, et al. Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus. Diagn Pathol. 2015;10:71.
30. Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M, et al. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol. 2015;45:2886-97.
31. Verma J, Arora V, Marwaha V, Kumar A, Das N. Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus. Lupus. 2005;14:273-9.
32. Alkhotani A. Neuropsychiatric Lupus. Sultan Qaboos Univ Med J. 2013;13:19-25.
33. Vanarsa K, Ye Y, Han J, Xie C, Mohan C, Wu T. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res Ther. 2012;14:R182.
34. Salinas-Carmona MC, Perez LI, Galan K, Vazquez AV. Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice. Autoimmunity. 2009;42:537-44.
35. Terrazas LI, Montero D, Terrazas CA, Reyes JL, Rodríguez-Sosa M. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int J Parasitol. 2005;35:1349-58.
36. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327-37.
37. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 2005;105:2549-56.